Literature DB >> 19517057

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.

Takeshi Okanoue1, Yoshito Itoh, Hiroaki Hashimoto, Kohichiroh Yasui, Masahito Minami, Tetsuo Takehara, Eiji Tanaka, Morikazu Onji, Joji Toyota, Kazuaki Chayama, Kentaro Yoshioka, Namiki Izumi, Norio Akuta, Hiromitsu Kumada.   

Abstract

BACKGROUND: Chronic hepatitis C (CHC) genotype 1b patients with high viral load are resistant to peginterferon (PEG-IFN) and ribavirin (RBV) combination therapy, especially older and female patients.
METHODS: To elucidate the factors affecting early and sustained viral responses (EVR and SVR), 409 genotype 1b patients CHC with high viral loads who had received 48 weeks of PEG-IFN/RBV therapy were enrolled. The amino acid (aa) sequences of the HCV core at positions 70 and 91 and of the interferon sensitivity determining region (ISDR) were analyzed. Host factors, viral factors, and treatment-related factors were subjected to multivariate analysis.
RESULTS: Male gender, low HCV RNA load, high platelet count, two or more aa mutations of ISDR, and wild type of core aa 70 were independent predictive factors for SVR. In patients with over 80% adherences to both PEG-IFN and RBV, male gender, mild fibrosis stage, and wild type of core aa 70 were independent predictors for SVR.
CONCLUSIONS: Independent predictive factors for SVR were: no aa substitution at core aa 70, two or more aa mutations in the ISDR, low viral load, high values of platelet count, mild liver fibrosis and male gender.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19517057     DOI: 10.1007/s00535-009-0087-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  36 in total

1.  Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

Authors:  Yoshiaki Iwasaki; Hiroshi Ikeda; Yasuyuki Araki; Toshiya Osawa; Keiji Kita; Masaharu Ando; Toshinari Shimoe; Kouichi Takaguchi; Noriaki Hashimoto; Toshitsugu Kobatake; Minoru Tomita; Mitsuhiko Kawaguchi; Haruhiko Kobashi; Kohsaku Sakaguchi; Yasushi Shiratori
Journal:  Hepatology       Date:  2006-01       Impact factor: 17.425

Review 2.  Classification of chronic hepatitis: diagnosis, grading and staging.

Authors:  V J Desmet; M Gerber; J H Hoofnagle; M Manns; P J Scheuer
Journal:  Hepatology       Date:  1994-06       Impact factor: 17.425

3.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase.

Authors:  Chee-Kin Hui; Tigist Belaye; Kevin Montegrande; Teresa Lyn Wright
Journal:  J Hepatol       Date:  2003-04       Impact factor: 25.083

5.  A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase.

Authors:  Takeshi Okanoue; Akiko Makiyama; Mika Nakayama; Yoshio Sumida; Hironori Mitsuyoshi; Tomoki Nakajima; Kohichiroh Yasui; Masahito Minami; Yoshito Itoh
Journal:  J Hepatol       Date:  2005-10       Impact factor: 25.083

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Naoki Hiramatsu; Nao Kurashige; Tsugiko Oze; Tetsuo Takehara; Shinji Tamura; Akinori Kasahara; Masahide Oshita; Kazuhiro Katayama; Harumasa Yoshihara; Yasuharu Imai; Michio Kato; Sumio Kawata; Hirohito Tsubouchi; Hiromitsu Kumada; Takeshi Okanoue; Shinichi Kakumu; Norio Hayashi
Journal:  Hepatol Res       Date:  2007-08-20       Impact factor: 4.288

8.  Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.

Authors:  Haruaki Shirakawa; Akihiro Matsumoto; Satoru Joshita; Michiharu Komatsu; Naoki Tanaka; Takeji Umemura; Tetsuya Ichijo; Kaname Yoshizawa; Kendo Kiyosawa; Eiji Tanaka
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

9.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

10.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Authors:  Andrew J Muir; Jeffrey D Bornstein; Paul G Killenberg
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  23 in total

Review 1.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Interferon-based therapy for chronic hepatitis C: current and future perspectives.

Authors:  Valli De Re
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

3.  Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.

Authors:  Itaru Ozeki; Jun Akaike; Yoshiyasu Karino; Tomohiro Arakawa; Yasuaki Kuwata; Takumi Ohmura; Takahiro Sato; Naohiro Kamiya; Ichimaro Yamada; Kazuaki Chayama; Hiromitsu Kumada; Joji Toyota
Journal:  J Gastroenterol       Date:  2011-05-10       Impact factor: 7.527

4.  Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Niwat Maneekarn
Journal:  Virusdisease       Date:  2016-01-18

5.  Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Authors:  Shiho Miyase; Katsuki Haraoka; Yoshihiro Ouchida; Yuko Morishita; Shigetoshi Fujiyama
Journal:  J Gastroenterol       Date:  2012-03-02       Impact factor: 7.527

6.  Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study.

Authors:  Yasunari Hiramine; Hirofumi Uto; Yasushi Imamura; Kazuaki Tabu; Yoshirou Baba; Takuya Hiwaki; Yukihiko Sho; Kenji Tahara; Hirofumi Higashi; Tutomu Tamai; Makoto Oketani; Akio Ido; Hirohito Tsubouchi
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

7.  Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

Authors:  Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakamoto; Yoshiyuki Suzuki; Naoki Hiramatsu; Fuminaka Sugauchi; Hiroshi Yatsuhashi; Namiki Izumi
Journal:  J Gastroenterol       Date:  2010-09-10       Impact factor: 7.527

Review 8.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

9.  A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia.

Authors:  Hiroki Tahara; Hitoshi Takagi; Ken Sato; Yasushi Shimada; Hiroki Tojima; Tomoyuki Hirokawa; Tatsuya Ohyama; Katsuhiko Horiuchi; Atsushi Naganuma; Hirotaka Arai; Satoru Kakizaki; Masatomo Mori
Journal:  J Gastroenterol       Date:  2011-05-19       Impact factor: 7.527

Review 10.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.